New eye gel passes safety test in cataract and glaucoma surgeries

NCT ID NCT07184437

Completed Disease control Sponsor: Bohus Biotech AB Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a gel called MINIVISC® PLUS, used during eye surgeries like cataract removal and glaucoma surgery to protect delicate tissues and keep the eye stable. Researchers checked if the gel was safe and worked well in 134 patients. The main focus was on eye pressure after surgery and signs of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MINIVISC® PLUS gel (a fermented ophthalmic viscosurgical device)
What this could lead to: If successful, this gel could be a safe and effective tool to protect the eye and maintain space during various eye surgeries.
What could go wrong: This is a completed study with results not yet published. The gel is already in use, so this trial mainly confirms its safety and performance rather than introducing a breakthrough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CATARACT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cataract corneal disorder glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CATARACT

Contacts and locations

Locations

Eye Clinic Falu Hosptal

Falun, Dalarna County, 791 82, Sweden
Optalmic Clinic Uddevalla Hospital

Uddevalla, Västra Götaland County, 451 53, Sweden
Optalmica Eye Clinic

Stockholm, Stockholm County, 183 34, Sweden
Opthalmic Clinic University Hospital Linköping

Linköping, Östergötland County, 581 85, Sweden
UZ Leuven

Leuven, 3000, Belgium
Ögonläkargruppen Odenplan

Stockholm, Stockholm County, 113 22, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.